ICAM1 and periodontitis: also found that the anti‐inflammatory effects of M2‐exos were attributed to specific interactions between lymphocyte function‐associated antigen 1 (LFA‐1) and very late activation 4 (VLA‐4) on their surfaces and intercellular adhesion molecule 1 (ICAM‐1) and receptor in LPS‐activated macrophages, allowing them to target inflammatory joints.[34] In summary, M2‐exos can be used as a simple and effective drug carrier with inflammatory targeting and anti‐inflammatory properties for treating periodontitis.